Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Microbes
100%
Radioimmunotherapy
100%
Monoclonal Antibody
45%
Immune System
27%
Immunocompromised Host
18%
Long-lived Radionuclides
18%
Clinical Protocols
18%
Patient Demographics
9%
Radiolanthanides
9%
Neutrophils
9%
Complement Immunity
9%
Lead-212
9%
Cellular Immunity
9%
Bismuth-212
9%
Microbicidal
9%
Cargo
9%
Opportunistic Infectious Diseases
9%
IgA Isotype
9%
In Cancer
9%
Therapeutic Window
9%
Radiation Sensitivity
9%
Immune Status
9%
Antimicrobial Therapy
9%
Binding Constant
9%
Disease Stage
9%
Radiation Dose
9%
Resistant Strains
9%
High Inoculum
9%
Fungi
9%
Novel Modalities
9%
Immune Defense
9%
Specific Monoclonal Antibodies
9%
Cellular Machinery
9%
Specific Patient
9%
Opportunistic Infections
9%
Immunology and Microbiology
Microorganism
100%
Monoclonal Antibody
100%
Immune System
50%
Isotype
50%
Adoptive Immunity
16%
Binding Affinity
16%
Cytokine
16%
Immunocompromised Patient
16%
Cell Body
16%
Isotope Labeling
16%
Neutrophil Granulocyte
16%
Infectious Agent
16%
Opportunistic Infection
16%
Inoculum
16%
Immunoglobulin A
16%
Infectious Disease
16%
Medicine and Dentistry
Radioimmunotherapy
100%
Infection
72%
Monoclonal Antibody
54%
Immune System
27%
Radioisotope
18%
Lead 212
9%
Therapeutic Window
9%
Patient Population
9%
Malignant Neoplasm
9%
Cell Body
9%
Cytokine
9%
Opportunistic Infection
9%
Immunoglobulin A
9%
Disease
9%
Cellular Immunity
9%
Neutrophil
9%
Immunocompromised Patient
9%
Pathogen
9%
Antimicrobial Therapy
9%
Binding Affinity
9%
Bismuth 212
9%